Acurx Pharmaceuticals, Inc.
ACXPHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. At a $6.1M market cap, Acurx Pharmaceuticals, Inc. ranks as a micro-cap company within healthcare. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Market Cap
$6.1M
Beta
-2.02
P/E (TTM)
—
P/E (Fwd)
-0.82
EPS (TTM)
$-2.44
EPS (Fwd)
$-1.75
ROE
-128.1%
ROA
-55.9%
Cash
$10.7M
Total Debt
$0
Free CF
-$3.4M
52W Change
-65.1%
Annual Financials
Cash vs Debt
Where ACXP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ACXP finished 32.86% below its 150-day moving average ($2.13) and 41.39% below its 200-day moving average ($2.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ACXP overbought or oversold?
At the September 3, 2026 close, ACXP's RSI(14) was 47.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Acurx Pharmaceuticals, Inc. reports $10.7M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$3.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -128.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -2.02 suggests ACXP is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ACXP.